ArticleThe oncologist2023

A Novel HRD Signature Is Predictive of FOLFIRINOX Benefit in Metastatic Pancreatic Cancer.

Kuei-Ting Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.